Levetiracetam Hikma (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A. This binding modulates the release of neurotransmitters, stabilising neuronal firing and decreasing hyper‑excitability. The resulting reduction in abnormal electrical activity underlies its ability to prevent seizure propagation.

The dosage of Levetiracetam Hikma is individualised and set by the treating physician based on the patient’s clinical condition, age, renal function and concomitant therapies. Healthcare professionals determine the appropriate infusion rate and total daily amount to achieve optimal seizure control.

Levetiracetam is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the potential risk. Limited data suggest it is excreted in breast milk; breastfeeding decisions should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Levetiracetam Hikma. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Compared with traditional agents such as valproate or carbamazepine, levetiracetam has a distinct mechanism (SV2A binding) and a relatively favourable drug‑interaction profile. It does not induce hepatic enzymes, reducing the likelihood of pharmacokinetic interactions. However, individual response varies, and clinicians consider efficacy, tolerability, comorbidities and potential side‑effects when selecting therapy.

Levetiracetam Hikma should be stored at ambient temperature, below 25 °C, protected from moisture and light. Keep the solution in its original packaging until use and avoid freezing. If the product is reconstituted for infusion, follow the manufacturer’s instructions regarding stability and discard any unused portion after the recommended time.

Levetiracetam Hikma is supplied as an intravenous solution and is administered by slow infusion into a vein. The infusion rate and total daily dose are determined by the prescribing clinician. It may be given as a single daily infusion or divided doses, depending on the therapeutic plan and patient tolerance.

Serious adverse reactions include severe allergic responses such as rash, swelling or anaphylaxis, as well as significant mood alterations like depression, suicidal ideation or aggression. Hematologic abnormalities such as thrombocytopenia or neutropenia have also been reported. Patients should be monitored closely for these events, and treatment should be discontinued if they occur.

Levetiracetam Hikma is contraindicated in individuals with a known hypersensitivity to levetiracetam or any of the formulation components. Caution is advised in patients with severe renal impairment where dose adjustment may be required, and in those with a history of serious psychiatric disorders until stability is confirmed.